Stocks · News reference

Ernexa Therapeutics shares are trading higher after the company announced new preclinical data independently validating the anti-tumor activity of its lead cell therapy candidate, ERNA-101, in combination with PD-1 checkpoint inhibition.

Jul 15, 2026, 2:09 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaJul 15, 2026, 6:11 PMVandana Singh
Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy
Ernexa Therapeutics reports independent preclinical validation of ERNA-101 with PD-1 therapy ahead of the planned 2026 IND filing.
Read original at benzinga
ERNA
BenzingaJul 15, 2026, 1:43 PMAvi Kapoor
Dow Gains Over 150 Points; Morgan Stanley Profit Tops Views
US stocks traded higher with Dow up 150 points. Consumer discretionary shares surged 1.3% while health care stocks fell 0.4%. Morgan Stanley beat earnings.
Read original at benzinga
AEHR CRDF ERNA LGHL MS
BenzingaJul 15, 2026, 11:53 AMBenzinga Newsdesk
Ernexa Therapeutics Announces Independently Conducted Study Validating Anti-Tumor Activity Of Its ERNA-101 Lead Cell Therapy Candidate Shows Complete Tumor Clearance, Durable Long-Term Survival; Investigational New Drug Submission Planned In Q3
Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced compelling new preclinical data independently
Read original at benzinga
ERNA